| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702538 | Urologic Oncology: Seminars and Original Investigations | 2017 | 8 Pages |
Abstract
N-cadherin is expressed in approximately 2/5 patients with NMIBC. Its expression is associated with adverse pathological features and higher risk of disease recurrence but not progression. N-cadherin could be incorporated in predictive tools to assist in recurrence prediction helping thereby in patient selection regarding adjuvant therapies and follow-up planning.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Mohammad Abufaraj, Shahrokh F. Shariat, Andrea Haitel, Marco Moschini, Beat Foerster, Piotr ChÅosta, Kilian Gust, Marek Babjuk, Alberto Briganti, Pierre I. Karakiewicz, Walter Albrecht,